a separate treatment-use formulation (0.5 mg and 1.0 mg base per vial, for treating growth hormone deficiency and growth failure in children) was approved September 26, 1997 under NDA 20-443
They promote fat splitting and prevent fat storage in the liver
This may indicate inadequate treatment intensity or an alternative neurological condition
Claims involving fat loss, obesity, glucose control, liver disease, sarcopenia, metabolism or anti-ageing could contribute to medicinal classification
By increasing the expression density of these receptors, the peptide enhances the sensitivity of the cellular environment to endogenous lipolytic stimuli
This prevents any single area from developing irritation, scar tissue, or lipodystrophy (a breakdown of fat tissue)